Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

How LabWare 8 Blocks Premature Lot Release in GxP-Regulated Pharma Environments

Lot release is the most critical step in pharmaceutical quality management because it determines whether a batch is safe for patient use. However, across the industry, deviations still occur where lots are released without full review and approval of all underlying samples or tests, creating serious compliance and data integrity risks.

In this client case, the Zamann Pharma Support team identified the key compliance gaps, conducted a structured GAP assessment, and designed a LabWare 8–based control approach to prevent premature lot release.

Challenges Faced

A detailed GAP analysis in Quality Management Systems is essential for identifying process deficiencies effectively.
  • Inspection Risk: Regulators such as FDA and EMA require complete evidence that all testing is finished before release, and missing reviews can lead to major observations and regulatory findings during inspection.
  • Human Factors: Operational pressure can lead to missed sample reviews, resulting in premature lot release decisions and increased risk of compliance deviations.
  • Disconnected Systems: When LIMS, QMS, and ERP are not fully integrated, lot status may appear ready even when required approvals and reviews are still incomplete.
  • Limited System Enforcement: Many organizations rely on SOPs instead of system-level controls, which increases dependency on human behavior and reduces enforcement reliability.

Zamann Pharma Support’s Approach

  • Automated Lot Blocking Configuration: LabWare 8 was configured to prevent lot release until all associated samples were fully reviewed and formally approved within the system workflow.
  • Review Visibility Enhancement: The system was set up to provide clear and real-time visibility of all pending sample reviews to improve operational control and decision-making.
  • Audit-Ready Data Integrity: Controls were implemented to ensure inspectors can clearly verify that incomplete releases are technically blocked by system-level enforcement.
  • Compliance Validation and Training: The solution was validated under CSV/CSA expectations and users were trained on the updated release workflow and compliance requirements.

Results Achieved

  • Zero Premature Releases: After implementation, deviations related to early lot release dropped to zero within the defined period, showing immediate process stabilization.
  • Improved Inspection Readiness: Audit inspections confirmed system-based enforcement of release controls, significantly reducing compliance risk during regulatory reviews.
  • Stronger Data Integrity: The system eliminated reliance on manual checks and enforced structured approval workflows to strengthen overall data integrity.
  • Operational Stability: Lot release processes became more controlled, predictable, and fully aligned with regulatory expectations and internal quality standards.
Laboratory
GMP qualification and lifecycle validation activities including IQ, OQ, and PQ supporting inspection readiness in pharmaceutical manufacturing.
Services

Qualification and Validation for GMP Systems

Our team supports the planning, execution, and maintenance of qualification and validation activities, including IQ, OQ, and PQ, to keep GMP-regulated systems compliant and under control.

Read More

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

FAQ

1. Why do batch release controls still fail even in validated LIMS environments?

Even in validated systems, failures usually occur when release logic is not fully enforced at configuration level, allowing incomplete sample review states to pass due to weak system constraints or misconfigured workflow rules.

2. What is the real regulatory risk behind “technically released but not fully reviewed” batches?

The core risk is data integrity breakdown under FDA 21 CFR Part 11 and GAMP5 expectations, where auditors treat incomplete review evidence as a critical system control failure, not a procedural deviation.

3. How does system-based blocking change inspection outcomes in batch release workflows?

System-based blocking shifts compliance from operator-dependent checks to enforced digital controls, which inspectors recognize as robust evidence that premature lot release is technically impossible within the validated system boundary.